Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, David Preiss et al.|The Lancet|2022Cited by 969
Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patientsNatalie Staplin, Bryan Williams|The Lancet|2023Cited by 261
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo, Hiddo J.L. Heerspink, Brendon L. Neuen et al.|The Lancet Diabetes & Endocrinology|2024Cited by 135
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trialPK Judge, A. Q. Adeleke, Natalie Staplin et al.|The Lancet Diabetes & Endocrinology|2023Cited by 107